Document is current
Any future updates will be listed below
-
Authors
Shien, Tadahiko https://orcid.org/0000-0003-3202-5512
Ishitobi, Makoto
Sasaki, Keita
Tanaka, Kiyo
Shimomura, Akihiko
Tsukioki, Takahiro
Sagara, Yasuaki
Kimura, Yuri
Terata, Kaori
Ishiba, Takayuki
Yasojima, Hiroyuki
Ono, Makiko
Goda, Kyoko
Naito, Yoichi
Fujisawa, Tomomi
Hara, Fumikata
Ogawa, Gakuto
Fukuda, Haruhiko
Iwata, Hiroji
,
-
Funding
Funding for this research was provided by:
Okayama University
- License Information
-
More Information
Article History
Received: 4 October 2025
Accepted: 26 December 2025
First Online: 31 January 2026
Declarations
:
: Dr. Shien reported grants from the Ministry of Health, Labour and Welfare of Japan and from the Japan Agency for Medical Research and Development (AMED) during the conduct of the study, as well as personal fees from Pfizer, Chugai, Lilly, Daiichi Sankyo, MSD, Eizai, AstraZeneca, Taiho, Nihonkayaku, Gilead. Dr. Hara reported the personal fees from Pfizer, Ili Lilly, Daiichi Sankyo, Kyowa Kirin, Chugai, MSD. Dr. Ogawa reported the grants from Japan Agency for Medical Research and Development and Ministry of Health, Labour and Welfare, Japan. Dr. Fukuda reported the grants from National Cancer Center and AstraZeneca, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited and the personal fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., CMIC Co., Ltd. Dr. Iwata reported the grants from Pfizer and Chugai, Daiichi Sankyo, AstraZeneca and personal fees from Daiichi Sankyo, Chugai, AstraZeneca, Lilly, MSD, Pfizer, Taiho, Kyowa Kirin. No other disclosures were reported.
: All methods were performed by the relevant guidelines and regulations. This study was approved by the Ethics Committee of National Cancer Center Hospital East Certified Review Board, and the approval reference number is CRB3180009. Informed consent was obtained from all participants involved in the study.
